메뉴 건너뛰기




Volumn 49, Issue 4, 2015, Pages 469-476

Radium-223 Dichloride: A Novel Treatment Option for Castration-Resistant Prostate Cancer Patients With Symptomatic Bone Metastases

Author keywords

adult medicine; cancer; clinical decision making; drug development and approval; drug trials; education; oncology; radioisotopes; supportive care

Indexed keywords

RADIUM CHLORIDE RA 223; ANTINEOPLASTIC AGENT; RADIOISOTOPE; RADIUM;

EID: 84924915161     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014565444     Document Type: Review
Times cited : (19)

References (15)
  • 1
    • 85081861374 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network (NCCN). NCCN guideline for patients: prostate cancer. Accessed March 1, 2014
    • National Comprehensive Cancer Network (NCCN). NCCN guideline for patients: prostate cancer. http://www.nccn.org/patients/guidelines/prostate/. Accessed March 1, 2014.
  • 2
    • 85081870599 scopus 로고    scopus 로고
    • National Cancer Institute at the National Institutes of Health. Prostate cancer: estimated new cases and deaths. Accessed February 13, 2014
    • National Cancer Institute at the National Institutes of Health. Prostate cancer: estimated new cases and deaths. http://www.cancer.gov/cancertopics/types/prostate. Accessed February 13, 2014.
  • 3
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • et al
    • Tannock IF,de Wit R,Berry WR, et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med. 2004;351:1502-1512
    • (2004) N Engl J Med , vol.351 , pp. 1502-1512
    • Tannock, I.F.1    de Wit, R.2    Berry, W.R.3
  • 4
    • 85081864574 scopus 로고    scopus 로고
    • American Cancer Society. Bone metastasis. Accessed April 17, 2014
    • American Cancer Society. Bone metastasis. http://www.can-cer.org/acs/groups/cid/documents/webcontent/003087-pdf.pdf. Accessed April 17, 2014.
  • 5
    • 34347244905 scopus 로고    scopus 로고
    • Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
    • et al
    • Nilsson S,Franzén L,Parker C, et al.Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.Lancet Oncol. 2007;8:587-594
    • (2007) Lancet Oncol , vol.8 , pp. 587-594
    • Nilsson, S.1    Franzén, L.2    Parker, C.3
  • 6
    • 84871926771 scopus 로고    scopus 로고
    • A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer
    • et al
    • Parker CC,Pascoe S,Chodacki A, et al.A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.Eur Urol. 2013;63:189-197
    • (2013) Eur Urol , vol.63 , pp. 189-197
    • Parker, C.C.1    Pascoe, S.2    Chodacki, A.3
  • 7
    • 84880428467 scopus 로고    scopus 로고
    • Alpha emitter radium-223 and survival in metastatic prostate cancer
    • et al
    • Parker C,Nilsson S,Heinrich D, et al.Alpha emitter radium-223 and survival in metastatic prostate cancer.N Engl J Med. 2013;369:213-223
    • (2013) N Engl J Med , vol.369 , pp. 213-223
    • Parker, C.1    Nilsson, S.2    Heinrich, D.3
  • 8
    • 85081866670 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): prostate cancer. November 20, 2014
    • National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): prostate cancer. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdfAccessed November 20, 2014.
  • 9
    • 85081863525 scopus 로고    scopus 로고
    • Wayne, NJ: ; :, Bayer HealthCare Pharmaceuticals Inc
    • Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2013:
    • (2013)
  • 10
    • 85081861657 scopus 로고    scopus 로고
    • Center for Drug Evaluation and Research. Application number 203971Orig1s000: pharmacology review(s). Accessed February 5, 2014
    • Center for Drug Evaluation and Research. Application number 203971Orig1s000: pharmacology review(s). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203971Orig1s000PharmR.pdf. Accessed February 5, 2014.
  • 11
    • 85081869115 scopus 로고    scopus 로고
    • Center for Drug Evaluation and Research. Application number 203971Orig1s000: clinical pharmacology and biopharmaceutics review(s). Accessed February 6, 2014
    • Center for Drug Evaluation and Research. Application number 203971Orig1s000: clinical pharmacology and biopharmaceutics review(s). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203971Orig1s000ClinPharmR.pdf. Accessed February 6, 2014.
  • 12
    • 85081861959 scopus 로고    scopus 로고
    • Horsham, PA: ; :, Janssen Biotech, Inc
    • Horsham, PA: Janssen Biotech, Inc; 2012:
    • (2012)
  • 13
    • 85081867144 scopus 로고    scopus 로고
    • Morristown, NJ: ; :, Actavis Inc
    • Morristown, NJ: Actavis Inc; 2013:
    • (2013)
  • 14
    • 85081868359 scopus 로고    scopus 로고
    • Northbrook, IL: ; :, Astellas Pharma US, Inc
    • Northbrook, IL: Astellas Pharma US, Inc; 2012:
    • (2012)
  • 15
    • 85081867467 scopus 로고    scopus 로고
    • Center for Drug Evaluation and Research. Application number 203971Orig1s000: medical review(s). Accessed February 5, 2014
    • Center for Drug Evaluation and Research. Application number 203971Orig1s000: medical review(s). http://www.accessdata.f-da.gov/drugsatfda_docs/nda/2013/203971Orig1s000MedR.pdf. Accessed February 5, 2014.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.